Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Adjuvant management of women with high-intermediate- and high-risk early-stage endometrial cancer remains controversial. Recently published results of GOG 249 revealed that vaginal brachytherapy plus chemotherapy (VBT + CT) was not superior to whole pelvic radiation therapy (WPRT) and was associated with more toxicities and higher nodal recurrences. This study examined off-study utilization of VBT + CT among women who met criteria for GOG 249 in the period prior to study publication.
Methods: Women diagnosed with FIGO IA-IIB endometrioid, serous, or clear cell uterine cancer between 2004-2015 and treated with hysterectomy and radiotherapy (RT) were identified in the National Cancer Database. Cochrane-Armitrage trend test was used to assess trends over time. Univariate and multivariate Cox analyses were performed to calculate odds ratio (OR) of VBT + CT receipt and hazard ratio (HR) of OS. Propensity-score matched analysis was conducted to account for baseline differences.
Results: 9956 women met inclusion criteria. 7548 women (75.8%) received WPRT while 2408 (24.2%) received VBT + CT in the study period. From 2004-2015, there was a significant increase in VBT + CT use (p < 0.001) with the largest overall increase occurring in 2009 to 22%. Factors significantly associated with VBT + CT receipt included higher socioeconomic status (p < 0.001), higher grade endometrioid cancer (p < 0.001), and aggressive histology (p < 0.001). After propensity-score matching, VBT + CT was associated with improved OS (HR 0.74, 95% CI 0.58-0.93); however, when stratified by FIGO stage, VBT + CT was only associated with improved OS for FIGO stage 1B (HR 0.62, 95% CI 0.44-0.87).
Conclusions: There was significant use of experimental arm off-study treatment in the United States prior to report of GOG 249 results. Providers should be cautious when offering off-study treatment utilizing an experimental regimen given uncertainty about efficacy and toxicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397368 | PMC |
| http://dx.doi.org/10.1016/j.ygyno.2019.09.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health State Utilities for Achondroplasia: A Time Trade-Off Study.
Value Health
September 2025
BioMarin Pharmaceutical Inc, London, England, UK.
Objectives: Achondroplasia is a rare genetic disorder that prevents the changing of cartilage to bone, leading to disproportionate short stature, which can have serious complications that affect quality of life. The aim of this study is to elicit health state utility values (HSUVs) corresponding to health states (HSs) describing the impact of achondroplasia, via a time trade-off valuation approach with the general public.
Methods: Ten HSs were defined for this time trade-off exercise.
A time trade-off study in the UK, Canada and the US to estimate utilities associated with the treatment of haemophilia.
Health Qual Life Outcomes
November 2024
Novo Nordisk A/S, Zurich, Switzerland.
Introduction: Haemophilia is a rare bleeding disorder caused by a deficient or absent clotting factor, leading to frequent bleeding. Multiple intravenous (IV) infusions have been the standard prophylactic treatment; however, newer treatment options involve less frequent subcutaneous (SC) injections. To inform future health economic evaluations, this study applied the time trade-off (TTO) method for estimation of utilities associated with haemophilia treatment for both people with the disease and potential caregivers.
View Article and Find Full Text PDFDaratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study.
Blood
November 2024
Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.
Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg IV) plus backbone chemotherapy in children with relapsed/refractory B-cell ALL (n = 7) after ≥2 relapses, and children and young adults with T-cell ALL (children, n = 24; young adults, n = 5) or LL (n = 10) after first relapse. The primary end point was complete response (CR) in the B-cell ALL (end of cycle 2) and T-cell ALL (end of cycle 1) cohorts, after which patients could proceed off study to allogeneic hematopoietic stem cell transplant (HSCT).
View Article and Find Full Text PDFHigh STI burden among a cohort of adolescents aged 12-19 years in a youth-friendly clinic in South Africa.
PLoS One
July 2024
The Aurum Institute, Rustenburg, South Africa.
Article Synopsis
- - Adolescents in sub-Saharan Africa are highly vulnerable to HIV, STIs, and unintended pregnancies, prompting a study in Rustenburg, South Africa that followed 223 participants aged 12-19 to better understand their unique healthcare needs over 12 months.
- - The study revealed that among sexually active participants, the incidences of HIV and STIs were notably higher for females, with significant statistics showing 1.5 HIV cases, 15.7 chlamydia cases, and 15.0 pregnancies per 100 person-years at risk.
- - Some participants, particularly younger ones, experienced unexpected pregnancies and STIs even without reported sexual activity; the study also faced disruptions due to the COVID-19 pandemic, requiring
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
June 2024
Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany; German CLL Study Group, University of Cologne, Cologne, Germany.
Article Synopsis
- The GAIA/CLL13 trial found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib combinations led to better undetectable measurable residual disease (MRD) rates and longer progression-free survival compared to traditional chemoimmunotherapy for untreated chronic lymphocytic leukaemia (CLL) patients.
- The trial was a phase 3 study involving 159 sites across Europe and the Middle East, enrolling patients aged 18 and older with specific health criteria and assigning them to different treatment groups, including standard chemoimmunotherapy and various venetoclax-based combinations.
- All treatment regimens were administered in cycles, with detailed protocols for each group, specifically focusing on